Riccardo Giannini
Overview
Explore the profile of Riccardo Giannini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
1737
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Giannini R, Moretti S, Ugolini C, Macerola E, Menicali E, Nucci N, et al.
J Clin Endocrinol Metab
. 2019 Mar;
104(8):3557-3575.
PMID: 30882858
Objectives: The understanding of the mechanisms underlying thyroid cancer immune escape can lead to the identification of new molecular targets and/or efficacy biomarkers. For this purpose, we performed immune expression...
12.
Association between DNA methylation profile and malignancy in follicular-patterned thyroid neoplasms
Affinito O, Salerno P, DAlessio A, Cuomo M, Florio E, Carlomagno F, et al.
Endocr Relat Cancer
. 2019 Feb;
26(4):451-462.
PMID: 30753136
Molecular differentiation between benign (follicular thyroid adenoma, FTA) and malignant (follicular thyroid carcinoma, FTC) thyroid neoplasms is challenging. Here, we explored the genome-wide DNA methylation profile of FTA (n.10) and...
13.
Ferrari S, Fallahi P, Ruffilli I, Elia G, Ragusa F, Paparo S, et al.
Gland Surg
. 2018 Sep;
7(Suppl 1):S19-S29.
PMID: 30175060
Different genetic mutations and other molecular alterations in papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC) can be detected in fine-needle aspiration (FNA) of thyroid nodules, and can be...
14.
Ali G, Bruno R, Savino M, Giannini R, Pelliccioni S, Menghi M, et al.
Arch Pathol Lab Med
. 2018 Jan;
142(4):480-489.
PMID: 29372843
Context: - Patients with non-small cell lung cancer harboring ALK receptor tyrosine kinase ( ALK), ROS proto-oncogene 1 ( ROS1), and ret proto-oncogene ( RET) gene rearrangements can benefit from...
15.
Poma A, Giannini R, Piaggi P, Ugolini C, Materazzi G, Miccoli P, et al.
Endocr Connect
. 2018 Jan;
7(1):124-132.
PMID: 29298844
The distinction between follicular thyroid carcinomas (FTCs) and follicular-patterned benign lesions is almost impossible on fine-needle aspiration cytology. Furthermore, minimally invasive FTCs (MI-FTCs) with less than 4 vascular invasion foci...
16.
Giannini R, Ugolini C, Poma A, Urpi M, Niccoli C, Elisei R, et al.
Thyroid
. 2017 Jul;
27(10):1267-1276.
PMID: 28679352
Background: The follicular variant (FV) of papillary thyroid cancer (PTC) is one of the most common variants of PTC. Clinically, non-infiltrative FVPTC is considered a low-risk variant of PTC, and...
17.
Bruno R, Ali G, Giannini R, Proietti A, Lucchi M, Chella A, et al.
Oncotarget
. 2016 Nov;
8(2):2758-2770.
PMID: 27835874
Malignant pleural mesothelioma (MPM) is a rare asbestos related cancer, aggressive and unresponsive to therapies. Histological examination of pleural lesions is the gold standard of MPM diagnosis, although it is...
18.
Rago T, Scutari M, Loiacono V, Santini F, Tonacchera M, Torregrossa L, et al.
Thyroid
. 2016 Nov;
27(1):103-110.
PMID: 27809694
Background: Thyroid ultrasound (US) elastography provides an estimation of tissue stiffness and is helpful to differentiate malignant from benign lesions. Tissue proprieties and molecules causing stiffness are not established. The...
19.
Bruno R, Giordano M, Giannini R, Ali G, Puppo G, Ribechini A, et al.
Mol Med Rep
. 2016 Jul;
14(3):2238-42.
PMID: 27430882
Lung adenocarcinoma patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements respond well to approved ALK inhibitors. However, to date, limited evidence is available regarding whether using circulating free tumor mRNA...
20.
Giannini R, Lupi C, Sensi E, Ali G, Proietti A, Boldrini L, et al.
Oncol Rep
. 2016 Jul;
36(2):1166-72.
PMID: 27373829
Activating EGFR mutations are important genetic alterations that have strong therapeutic implications for non-small cell lung cancer (NSCLC) patients. However, the role of KRAS mutations in this process is still...